|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
Valuation Estimation |
EPS (Current/Estimated)
1.95/3.98
|
Enterprise Value
2.10B
|
Balance Sheet |
Book Value Per Share
9.48
|
Cash Flow |
Cash Flow Yield
0.11
|
Income Statement |
Total Revenue
582.02M
|
Operating Revenue Per Share
9.53
|
Industry Comparison
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
Quotes are at least 15-min delayed:2024/10/31 18:43 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
|
|||
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX(pitolisant), is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and used for the treatment of cataplexy in adult patients with narcolepsy. |